Arrowhead Pharmaceuticals reported that its gene silencing candidates helped obese people lose weight in early studies.[1] These are drugs using the RNA interference mechanism to suppress genes associated with obesity.[1][2] A Phase 1/2a study of ARO-INHBE is ongoing, evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeated doses in obese adults.[1][2] The study is double-blind with dose escalation and includes adults with obesity, including those with type 2 diabetes, taking tirsepatide.[1][2] The second part of the study will start after the safety evaluation from the first part until the 43rd day.[1][2] Treatment can dramatically improve patient outcomes by reducing fat mass, as obesity increases the risk of diabetes, heart disease, and stroke.[1] Arrowhead is planning a webinar with preliminary data on ARO-INHBE and ARO-ALK7 on January 6, 2026.[4]